

Healthcare resource utilisation and cost analysis associated with opioid analgesic use for non-cancer pain: A case-control, retrospective study between 2005 and 2015

British Journal of Pain
2021, Vol. 0(0) 1–14
© The Author(s) 2021



Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/20494637211045898
journals.sagepub.com/home/bjp



Emma Davies¹ , Ceri J Phillips¹, Mari Jones² and Bernadette Sewell¹

Abstract

Objective: To examine differences in healthcare utilisation and costs associated with opioid prescriptions for non-cancer pain issued in primary care.

Method: A longitudinal, case-control study retrospectively examined Welsh healthcare data for the period 1 January 2005–31 December 2015. Data were extracted from the Secure Anonymised Information Linkage (SAIL) databank. Subjects, aged 18 years and over, were included if their primary care record contained at least one of six overarching pain diagnoses during the study period. Subjects were excluded if their record also contained a cancer diagnosis in that time or the year prior to the study period. Case subjects also received at least one prescription for an opioid analgesic. Controls were matched by gender, age, pain-diagnosis and socioeconomic deprivation. Healthcare use included primary care visits, emergency department (ED) and outpatient (OPD) attendances, inpatient (IP) admissions and length of stay. Cost analysis for healthcare utilisation used nationally derived unit costs for 2015. Differences between case and control subjects for resource use and costs were analysed and further stratified by gender, prescribing persistence (PP) and deprivation.

Results: Data from 3,286,215 individuals were examined with 657,243 receiving opioids. Case subjects averaged 5 times more primary care visits, 2.8 times more OPD attendances, 3 times more ED visits and twice as many IN admissions as controls. Prescription persistence over 6 months and greater deprivation were associated with significantly greater utilisation of healthcare resources. Opioid prescribing was associated with 69% greater average healthcare costs than in control subjects. National Health Service (NHS) healthcare service costs for people with common, pain-associated diagnoses, receiving opioid analgesics were estimated to be £0.9billion per year between 2005 and 2015.

Conclusion: Receipt of opioid prescriptions was associated with significantly greater healthcare utilisation and accompanying costs in all sectors. Extended prescribing durations are particularly important to address and should be considered at the point of initiation.

Keywords

Opioid analgesics, non-cancer pain, resource utilisation, healthcare costs, cost analysis

How this fits in

It is known that opioid analgesics can have long-term, harmful effects other than misuse and dependence. Previous studies examined the association between healthcare utilisation and the presence of opioid-induced adverse effects or misuse. This study examined the relationship between opioid prescribing for a range of pain-

¹College of Human and Health Sciences, Swansea University, Swansea, UK

²Swansea Centre for Health Economics, Swansea University College of Human and Health Sciences, Swansea, UK

Corresponding author:

Emma Davies, College of Human and Health Sciences, Swansea University, Singleton Park, Sketty Lane, Swansea, Wales, SA2 8PP, UK.

Email: esd Davies500@gmail.com

associated conditions and all-cause healthcare utilisation. Receipt of opioid prescriptions, particularly for durations of more than 6 months, were associated with a significant increase in healthcare utilisation and associated costs, when compared to a similar population who did not use opioid analgesics.

Introduction

Opioid prescribing has markedly increased in the United Kingdom (UK) since the early 2000s.^{1–8} In Wales, opioid prescribing rates rose 44% (from 692 to 994 prescriptions per 1000 population) between 2005 and 2015.³ Reasons for the widespread use of opioids are manifold but rising prevalence of chronic non-cancer pain is often cited.^{10–13} A major contributor to continued opioid prescribing may be the paucity of non-pharmacological support to live more effectively with painful conditions.^{14–16} Socioeconomic costs of pain are substantial,^{17,18} with back pain estimated to cost the UK economy £10 billion per year.¹⁹

The focus of discussion around opioid prescribing is commonly the risk of dependence and misuse.^{20–24} Studies examining healthcare utilisation and costs associated with opioid misuse disorders^{25,26} found that incremental healthcare costs associated with prescription opioid misuse in Europe were estimated between €900 to €2551 per person per year, with annual healthcare costs up to €279,927 per 100,000 population.²³

Other harms of opioids especially when used at high dose and for longer durations have been acknowledged.^{27,28} Adverse effects such as constipation, nausea, vomiting and sedation are well known, identified and managed routinely, whatever the underlying pain-related diagnosis.^{29–32} Other harms of opioid analgesics include endocrine disorders,³³ depression,^{34,35} respiratory depression,^{36,37} sleep impairment,³⁸ falls and fractures,^{39–41} which, whether or not recognised as related to opioid use, will require additional healthcare intervention and support.

Our study is the first to compare healthcare resource utilisation and associated costs, in a large cohort of people with recorded pain-related diagnoses where case subjects were receiving opioid prescriptions and control subjects were not, in Wales between 2005 and 2015. The findings of our study highlight a potential consequence of opioid analgesic prescribing which is not often discussed. It provides a baseline on which to develop further research to examine how opioid-related healthcare utilisation and costs may be mitigated within a system of scant resource.

Method

Study design and data source

A retrospective, longitudinal case-control study design was used. Individual's anonymised data were extracted

from the Secure Anonymised Information Linkage (SAIL) databank, part of the national e-health records research infrastructure for Wales.^{42,43} Each individual with records in the SAIL databank was allocated a unique anonymised linkage field (ALF) number allowing cross-linking between different datasets. Data from all individuals aged 18 years and over, without a recorded diagnosis of cancer between 2004 and 2015 on their primary care medical record was included in the primary data extraction.

Data were taken from the Welsh longitudinal general practice (WLGP) source, downloaded directly from electronic health records in GP practices around Wales; the Welsh demographic service dataset (WDS); patient episode database Wales (PEDW) which records all inpatient (IN) and day-case hospital activity; emergency department (ED) and outpatient (OPD) data, which is collated by Digital Health and Care Wales (previously National Health Service (NHS) Wales Informatics Service, NWIS).⁴⁴

Cohort identification

Read codes, a thesaurus of clinical terms used to record interactions, diagnoses and interventions in Primary Care settings, were used to identify the case and control cohorts using the NHS Information Authority's Clinical Terminology Browser and accessed via the SAIL secure gateway. Read codes for six commonly occurring conditions associated with persistent pain, rheumatoid and osteoarthritis, neck and back pain, fibromyalgia and neuropathic pain, were compiled ([Supplementary file 1](#)) and used to identify subjects within the WLGP datasets. Demographic data were collated for each ALF and included gender, age, and deprivation level (based on Welsh Index of Multiple Deprivation 2011, WIMD).⁴⁵

Opioid prescription identification

Read codes were compiled for all oral and transdermal opioid medicines commonly prescribed as analgesics in Wales, as previously described³ ([Supplementary file 2](#)). The list included combination products, for example, paracetamol and codeine (co-codamol), but excluded those licensed for the management of misuse and injectable opioids.⁴⁶

Identification of case and control subjects

During dataset preparation, searches found 657,243 subjects with the defined, non-cancer conditions listed on their primary care medical record during the study period and who had received at least one prescription

for an opioid analgesic between 2005 and 2015. That group was classified as case subjects. There were 101,176 who matched case subjects by pain-diagnosis, gender, age and deprivation score but did not receive opioid prescriptions and so were used as control subjects. Consequently, every control subject was matched to multiple case subjects, a method recommended by SAIL and described in the literature.⁴⁷ For example, if a control subject had 6 years of medical records without receiving an opioid prescription, they could potentially be matched to case subjects who had received opioid analgesic prescriptions for any period up to 6 years. This effectively provided 2,628,972 control subjects.

Prescription persistence

At the time of the study, SAIL was not able to access data on dose instructions or quantity of medicine prescribed in Primary Care. Those variables can be used to estimate daily dose and the likely duration of the prescription.¹ An estimated measure was therefore developed, considering recommendations that the quantity of medicine given on a controlled drug prescription should not exceed more than 30 days' supply.⁴⁶ In the absence of prescribed quantity, it was assumed that if prescriptions were issued to the same individual within 31 days of each other, it was more likely the individual was consistently using opioid analgesics. The duration of 31.5 days maximum between prescriptions as a marker of continuous prescribing in large datasets was previously described by Braden et al. {Braden.2010}. The duration between each prescription issued to any individual was calculated using the recorded 'event dates' from the Primary Care General Practice (GP) dataset. Prescribing persistence (PP) was calculated as the number of days of consecutive prescriptions, when subsequent prescriptions were issued within 31 days of each other. If the period between prescriptions was longer than 31 days, it was classed as a new period of prescribing. Case subjects were stratified by PP of less than or more than 6 months.

Statistical analysis

Case subjects' data were collected from the first opioid prescription until 31 days after the last recorded issue or until death and compared to control subjects' data for the same duration. Healthcare attendances, tests and investigations for the period opioid prescriptions were received for each subject were counted, totalled and compared.

Due to the large sample size in both arms of the study (case and control), we determined parametric tests

could provide accurate analysis. Central limit theorem suggests when sample size is large, distribution tends to normal even if the population itself is not normally distributed.^{4,48} Analysis was undertaken using SPSS version 26.⁴⁵ Descriptive statistics were used to compare case and control groups. We used two-way analysis of variance (ANOVA) to examine inter-dependence of different variables, for example, male-female and case-control. An interaction effect between factors was deemed significant at 5%. Where there was significant interaction, univariate tests (independent t-test or one-way ANOVA) were conducted, with a significance level of 5%. Bonferroni-Holm sequential corrections were used to adjust for Type I error rate inflation in multiple comparisons.⁴⁶

Linear regression

Multiple linear regression analyses were used to predict which, if any, variables affected attendance in Primary Care (number of appointments) as well as OPD, ED or IP attendances. The factors used to make the predictions were opioid prescription, age, gender, deprivation status (WIMD2011), recorded diagnosis of depression and/or anxiety and whether an opioid prescription was issued or not, where prescriptions were issued and if they persisted for less or more than 6 months.

Cost analysis

Cost analysis was undertaken from a UK NHS perspective. Costs included primary care GP attendances, staff time, tests, investigations and imaging, ED and OPD department attendances and IP admissions which included day/night charges and excess day charges. Weighted average costings were calculated from nationally available standard NHS unit costs for 2015^{51,52} taking account of the number of attendances in each area (e.g. outpatient department, inpatient admission) and the nature of said attendance (e.g. elective, or non-elective admission; [Supplementary files 3 & 4](#)). General practice attendance costs were weighted according to published data giving standardised proportions of attendances with general practitioners compared to other professionals in Primary Care, such as nurses.⁴⁹ Data were not available to calculate drug costs.

Research approvals

This research was approved by the Information Governance Review Panel (IGRP) of the Secure Anonymised Information Linkage databank (SAIL), based in Swansea University (SAIL identification number: 0507).

Patient and public involvement statement

There was no direct patient involvement in development and design of this study. However, the SAIL databank has members of the public who provide advice and give recommendations on safeguarding and ethical approval via a Consumer Panel. Panel members also provide input to the IGRP, which approves all data applications.

Results

Overall healthcare utilisation

Records of 3,286,215 individuals aged 18 years and over were analysed (Table 1). Between 2005 and 2015, 190,984,317 GP appointments, 22,239,332 OPD appointments, 2,819,268 visits to ED and 8,698,222 hospital admissions (including day-case procedures) were recorded for the 3.2 million people included in the study.

On average, between 2005 and 2015, case subjects had nearly 5 times more GP interactions than controls (160.5 vs 32.5 visits per person (vpp) respectively, $p < 0.001$) (Table 2). Outpatient appointments were

almost three times more frequently recorded for case subjects (13.9 vpp) than controls (5.0 vpp, $p < 0.001$).

Emergency department attendance was three times more frequent for people receiving opioid prescriptions (1.89 vpp) than controls (0.6 vpp, $p < 0.001$). Case subjects had twice as many hospital admissions as controls (4.6 vs 2.2 admissions per person (app), $p < 0.001$) (Table 2). Despite fewer admissions, control subjects had 6% longer length of stay per admission, compared to cases (17.3 days versus 16.4 days, respectively).

Healthcare resource utilisation associated with PP

Opioid PP of more than 6 months (long-term) was associated with a significant increase in healthcare utilisation, compared to durations less than 6 months (short term) or controls (Figure 1). Three times as many GP visits were recorded for long-term users (198.8 vpp), compared to short-term durations of prescribing (67.7 vpp, $p < 0.001$).

Long-term use was associated with 2.8 times more OPD appointments (17.4 vs 5.6 vpp) and 2.4 times

Table 1. Characteristics of the two groups of study subjects.

Characteristic	Case	Controls when matched
Number of subjects	657,243	2,628,972
Gender (% of total)		
Male	273,057 (41.5)	1,092,228 (41.5)
Female	384,186 (58.5)	1,536,744 (58.5)
Age (years), mean (SEM)	57.0 (0.02)	57.1 (0.01)
Age group (years), n (%)		
18–24	12,666 (1.9)	69,028 (2.6)
25–44	166,078 (25.3)	686,319 (26.1)
45–64	240,332 (36.6)	926,868 (35.3)
65–74	112,002 (17.0)	413,295 (15.7)
75–84	80,161 (12.2)	316,659 (12.0)
≥85	46,004 (7.0)	216,803 (8.2)
Welsh Index of Multiple Deprivation quintile*, n (%)		
WIMD1	153,649 (23.4)	614,596 (23.4)
WIMD2	136,752 (20.8)	547,008 (20.8)
WIMD3	137,653 (20.9)	550,612 (20.9)
WIMD4	113,083 (17.2)	452,332 (17.2)
WIMD5	116,106 (17.7)	464,424 (17.7)
Opioid-group prescribed at end of prescribing period**		
Weak	594,939 (90.5)	
Strong	62,304 (9.5)	
Recorded diagnoses, n (%)		
Depression and/or anxiety	183,660 (27.9)	241,872 (9.2)

*Deprivation quintile based on Welsh Index of Multiple Deprivation 2011. WIMD1 = most deprived, WIMD5 = least deprived. **Weak opioids include codeine, dihydrocodeine and tramadol; strong opioids include buprenorphine, fentanyl, morphine, oxycodone and tapentadol (Supplementary file 2).

Table 2. Comparison of healthcare utilisation between case subjects (in receipt of opioid prescriptions) and controls (no opioids) between 2005 and 2015.

Mean (standard deviation)	Case	Control	Difference case- controls (95% CI)	Case versus control p -value ^{**} (d_{Cohen})
Number of GP attendances				
Total	105,457,258	85,527,059	127.92 (127.56–128.28)	<0.001 (0.96)
Mean (SD)	160.5 (146.3)	32.5 (56.8)		
Prescribing persistence (cases only)				
<6 months	67.7 (77.6) ^a			
>6 months	198.8 (150.8) ^a			
Deprivation quintile* ^{***}				
WIMD1	167.2 (149.7)	36.2 (57.7)	131.03 (130.27–131.79)	<0.001 (0.96)
WIMD2	164.7 (148.6)	33.7 (58.9)	130.95 (130.15–131.76)	<0.001 (0.97)
WIMD3	162.3 (147.5)	31.9 (55.8)	130.39 (129.60–131.20)	<0.001 (0.97)
WIMD4	154.9 (144.5)	30.3 (55.5)	124.56 (123.73–125.44)	<0.001 (0.95)
WIMD5	149.8 (137.8)	29.2 (55.3)	120.55 (119.75–121.36)	<0.001 (0.96)
Number of outpatient attendances				
Total	9,140,922	13,098,410	8.93 (8.88–8.97)	<0.001 (0.50)
Mean (SD)	13.9 (19.4)	5.0 (10.0)		
Prescribing persistence (cases only)				
<6 months	5.6 (10.1) ^b			
>6 months	17.4 (21.2) ^b			
Deprivation quintile* ^{***}				
WIMD1	15.2 (20.7)	5.3 (10.0)	9.83 (9.72–9.93)	<0.001 (0.52)
WIMD2	14.4 (19.9)	5.1 (10.4)	9.28 (9.17–9.38)	<0.001 (0.50)
WIMD3	13.5 (19.0)	5.0 (9.7)	8.52 (8.42–8.62)	<0.001 (0.49)
WIMD4	13.0 (18.4)	4.6 (9.3)	8.44 (8.33–8.55)	<0.001 (0.50)
WIMD5	13.0 (18.4)	4.8 (10.7)	8.30 (8.17–8.40)	<0.001 (0.48)
Number of emergency department attendances				
Total	1,243,641	1,566,627	1.30 (1.29–1.30)	<0.001 (0.42)
Mean (SD)	1.89 (3.4)	0.6 (1.8)		
Prescribing persistence (cases only)				
<6 months	0.96 (1.9) ^c			
>6 months	2.3 (3.8) ^c			
Deprivation quintile* ^{***}				
WIMD1	2.3 (3.9)	0.77 (2.1)	1.53 (1.51–1.55)	<0.001 (0.42)
WIMD2	2.4 (3.8)	0.65 (1.7)	1.39 (1.37–1.41)	<0.001 (0.40)
WIMD3	1.8 (3.2)	0.55 (1.9)	1.24 (1.23–1.26)	<0.001 (0.42)
WIMD4	1.64 (2.9)	0.53 (1.4)	1.11 (1.09–1.13)	<0.001 (0.42)
WIMD5	1.5 (2.6)	0.41 (1.2)	1.12 (1.10–1.13)	<0.001 (0.46)
Number of inpatient admissions				
Total	3,021,645	5,676,577	2.44 (2.42–2.46)	<0.001 (0.30)
Mean (SD)	4.6 (8.5)	2.2 (6.3)		
Prescribing persistence (cases only)				
<6 months	2.9 (6.2) ^d			
>6 months	5.3 (9.2) ^d			
Deprivation quintile* ^{***}				
WIMD1	4.9 (8.1)	2.3 (4.8)	2.62 (2.58–2.66)	<0.001 (0.35)
WIMD2	4.8 (8.7)	2.2 (4.7)	2.60 (2.55–2.64)	<0.001 (0.32)
WIMD3	4.5 (8.3)	2.3 (8.3)	2.19 (2.14–2.24)	<0.001 (0.26)
WIMD4	4.4 (9.0)	2.0 (6.4)	2.43 (2.37–2.48)	<0.001 (0.29)
WIMD5	4.2 (8.3)	1.9 (6.9)	2.31 (2.26–2.37)	<0.001 (0.29)

(continued)

Table 2. (continued)

Mean (standard deviation)	Case	Control	Difference case- controls [95% CI]	Case versus control <i>p</i> -value ^{**} (<i>d</i> _{Cohen})
Length of stay (days)				
Total	10,758,522	45,482,557	-0.93 [-1.09 to -0.78]	<0.001 [-0.02]
Mean (SD)	16.4 (54.7)	17.3 (64.9)		
Prescribing persistence (cases only)				
<6 months	10.4 (46.7) ^e			
>6 months	18.8 (57.5) ^e			
Deprivation quintile* ***				
WIMD1	17.6 (58.6)	17.9 (65.8)	-0.37 [-0.71 to -0.04]	<0.001 [-0.006]
WIMD2	16.9 (56.4)	18.0 (72.9)	-1.11 [-1.50 to -0.76]	<0.001 [-0.02]
WIMD3	16.5 (53.6)	18.9 (62.1)	-2.41 [-2.74 to -2.08]	<0.001 [-0.04]
WIMD4	15.0 (49.6)	15.1 (55.8)	-0.06 [-0.40 to -0.27]	0.710 [-0.001]
WIMD5	15.3 (53.4)	15.9 (65.4)	-0.55 [-0.91 to -0.19]	<0.001 [-0.01]

*Deprivation quintile based on Welsh Index of Multiple Deprivation 2011. WIMD1 = most deprived, WIMD5 = least deprived ***p*-value < 0.05 = significant ***This remained statistically significant after Bonferroni-Holm correction.

^a*p* < .001, *d*_{Cohen} = 1.3, mean difference 131.10 [95% CI 130.54–131.65].

^b*p* < .001, *d*_{Cohen} = .88, mean difference 11.76 [95% CI 11.68–11.84].

^c*p* < .001, *d*_{Cohen} = .51, mean difference 1.32 [95% CI 1.31–1.33].

^d*p* < .001, *d*_{Cohen} = 0.47, mean difference 2.44 [95% CI 2.40–2.50].

^e*p* < .001 *d*_{Cohen} = -.006, mean difference 8.41 [95% CI 8.14–8.68].

more ED. attendances (2.3 vs 0.96 vpp) than short term. Inpatient admissions were 1.8 times more frequent with long-term (5.3 app) than short-term opioid use (2.9 app).

Healthcare resource utilisation associated with differing levels of socioeconomic deprivation

Statistically significant, albeit empirically modest differences, increases in healthcare attendance with rising deprivation (Table 2), were noted within case and control groups (Figure 2).

Case subjects had around 1.5 times more ED. visits recorded (2.3 vpp) in the most deprived quintiles compared the least deprived (1.5 vpp, *p* < 0.001) with similar differences noted in the control group (Table 2). Greater socioeconomic deprivation was also associated with a higher number of inpatient admissions and length of stay in case and control subjects.

Factors associated with healthcare use

Multiple linear regression results indicated that the model was a good predictor of the number of attendances in Primary Care (GP). An *R*² of 0.457, SE = 71.75 (*R* = 0.676), meant 45.7% of the variation in the original data could be explained by the model. The models for predicting factors contributing to outpatient attendance (*R*² = 0.134, SE = 12.08), ED attendance (*R*² = 0.081, SE = 2.14) and inpatient admission (*R*² = 0.047, SE = 5.51) were less reliable.

Based on the regression output, the strongest predictors for attendance in any healthcare sector was

being in receipt of opioid analgesic prescriptions for more than 6 months (Table 3). In Primary Care, long-term prescribing increased attendance by on average 143.5 visits (SE = 0.121, *p* < 0.001) and receiving an opioid less than 6 months increased attendances by 34.3 visits (SE = 0.171, *p* < 0.001). In contrast, outpatient attendances and inpatient admissions were inversely affected by opioid prescribing (Table 3). Male gender negatively impacted GP visits ($\beta_n = -10.4$ visits, SE = 0.081, *p* < 0.001), outpatient attendance ($\beta_n = -1.24$ attendances, SE = 0.014, *p* < 0.001), ED visits ($\beta_n = 0.068$ visits, SE = 0.002, *p* < 0.001) and inpatient admissions ($\beta_n = -0.227$ admissions, SE = 0.006, *p* < 0.001). Attendance in all sectors increased in likelihood with increasing socioeconomic deprivation (Table 3). Age was associated with an increase in attendance in all healthcare settings (Table 3).

Cost analysis

The average cost of healthcare utilisation was estimated to be £11,096.49 per person (pp) for the study period (Figure 3). Case subject costs (£16,453.35 pp) were on average 1.7 times (68% higher) than estimated for the control group (£9757.27 pp, *p* < 0.001) (Table 4). Using actual subject numbers from SAIL (cases = 657,243 and controls = 101,176), total estimated healthcare costs for people with recorded diagnoses of the six pain-associated conditions was £11.8 billion over 11 years, averaging just under £1.1 billion per year. People receiving opioid




Figure 1. Comparison of healthcare utilisation stratified by PP of greater or less than 6 months and compared to control subjects (not prescribed opioid analgesics). Insert: detail of resource utilisation comparison for outpatient, ED attendances, inpatient admissions and length of stay [given in days]. Note: PP: prescribing persistence; ED: emergency department;

prescriptions accounted for 82% (£0.9 billion) of the yearly costs, without factoring in medicines. The data used for this study was representative of 78% of the Welsh population, so assuming this was a representative population, and inflating this cost to account for the entire Welsh population, annual healthcare costs could be as much as £1.4 billion per year for those with the listed diagnoses and £1.2 billion allocated to those also receiving opioid medicines.

One-way sensitivity analysis confirmed an increase in healthcare utilisation and its consequent costs, of more than 1.5 times (50% increase) would be required in the control group, to become equivalent to the averages noted in case subjects (Table 4).

Discussion

Summary

We used a large dataset to examine differences in healthcare utilisation in two diagnostically matched cohorts, who either received, or did not receive, opioid analgesic prescriptions. Significantly more appointments for people prescribed opioids were noted in all healthcare sectors, when compared to people with similar medical history but not prescribed opioid analgesics. Prescribing persistence of more than 6 months was most strongly associated with increased healthcare

utilisation and consequent costs. Receiving opioid prescriptions and living in areas of high socioeconomic deprivation appeared associated with greater healthcare utilisation than high levels of deprivation alone.

The cost analysis undertaken suggests that a large reduction in healthcare utilisation amongst individuals prescribed opioids would be required in order to bring costs in-line with people who are not prescribed opioid analgesics, despite similar conditions. These results are important given the high burden of opioid prescribing in Wales,³ the UK more widely,^{2,5,54} and the concerns expressed^{32,55-57} about opioid-induced long-term harms.

Comparison with existing literature

Increased healthcare utilisation following the initiation of opioids has been reported across the world.⁵⁵⁻⁶⁰ Healthcare use increased following the first prescription for opioid therapy, with costs further influenced by the drug prescribed in a German cohort.⁵⁵ Studies have found that whilst healthcare utilisation, and therefore costs, increase significantly following initiation, it appears to reduce with persistent prescribing, although not to pre-prescription levels.^{59,61} Chang and colleagues observed greater total healthcare costs for people receiving long-term opioids than people with a diagnosed opioid-use disorder {Chang:2018}.




Figure 2. Comparison of healthcare utilisation by socioeconomic deprivation using Welsh Index of Multiple Deprivation 2011 (WIMD2011). WIMD1 = most socioeconomically deprived, WIMD5 = least socioeconomically deprived.

2 US study reported twice as many healthcare interactions for chronic opioid use (>180 days) compared to acute use (less than 10 days),⁶² which compares to our study, where long-term users had 3 times as many GP and OPD visits and twice as many visits to ED compared to short-term users. Thornton et al. (2018) showed similar increases in inpatient in the first 120 days after initiation for individuals who received at least 90 consecutive days of opioid analgesics (from 1.5% to 10.9% of those prescribed chronic opioids compared to 1.1%–5.4% of non-chronic prescribing).⁵⁸

Comparing costs between the United Kingdom and other countries can be hampered by differences in healthcare systems and the manner by which tariffs are determined. The increased healthcare utilisation and associated costs demonstrated in our study are, however, consistent with other studies' findings among people prescribed opioid analgesics.^{59,61,62}

Strengths and limitations

Our study is the first to examine the association of opioid analgesic prescribing and overall healthcare

utilisation in Wales. The SAIL databank allows access to data for 78% of the Welsh population and our study included more than two million subjects, so is highly likely to be representative of the population.

Limitations were in part, due to restrictions in data availability and extraction. Matching of case and control subjects used a method advocated by SAIL⁶³ but was hampered by the disproportionate number of individuals with the diagnoses of interest also receiving opioid analgesic prescriptions. Further research is needed in Wales, to provide more detailed analysis, controlling for non-pain comorbidities, to accurately determine the impact of prescribed opioid use on the type of health care accessed.

Lists of read codes had to be scaled down to meet the workload capacity of the databank employees who undertake the data extraction and this likely led to underestimation of healthcare utilisation. For example, it was not possible to differentiate between the type of admission (e.g. elective, or non-elective) or the admission diagnosis recorded. Further research is needed to determine more accurate associations between

opioid prescribing, investigations and all-cause healthcare utilisation.

The SAIL databank did not have access to community pharmacy dispensing data, which precluded medication costs in the analysis. Whilst we used a

measure of prescription persistence described in other studies,^{43,58} we acknowledge timings of prescriptions do not confirm continued use by the individual and so are an estimate. Improved access to information on dose and quantity of opioid analgesics prescribed would

Table 3. Output from multiple linear regressions to predict number of healthcare attendances.

Variable (β_n)	Value (standard error), p -value**			
	<i>General practice</i>	<i>Outpatient</i>	<i>Emergency department</i>	<i>Inpatient admission</i>
R^2	457 (71.75)	0.134 (12.08)	0.081 (2.14)	0.047 (5.510)
R	0.676	0.366	0.284	0.217
β_0 equation constant	-26.24 (0.138)	1.193 (0.023)	0.680 (0.004)	
<i>Opioid prescription</i>				
<i>Under 6 months</i>	34.329 (0.171), <0.001	0.777 (0.029), <0.001	-0.392 (0.013), <0.001	-0.392 (0.013), <0.001
<i>Over 6 months</i>	143.501 (0.121), <0.001	11.649 (0.020), <0.001	1.540 (0.004), <0.001	1.614 (0.009), <0.001
<i>Male</i>	-10.419 (0.081), <0.001	-1.240 (0.014), <0.001	0.068 (0.002), <0.001	-0.227 (0.006), <0.001
<i>Deprivation quintile*</i>				
WIMD2	-2.122 (0.119), <0.001	-0.342 (0.020), <0.001	-0.173 (0.009), <0.001	-0.173 (0.009), <0.001
WIMD3	-3/.780 (0.119), <0.001	-0.717 (0.020), <0.001	-0.156 (0.009), <0.001	-0.156 (0.009), <0.001
WIMD4	-5.845 (0.126), <0.001	-1.087 (0.021), <0.001	-0.394 (0.010), <0.001	-0.394 (0.010), <0.001
WIMD5	-7.180 (0.126), <0.001	-0.974 (0.021), <0.001	-0.530 (0.010), <0.001	-0.530 (0.010), <0.001
<i>Diagnosis of depression/ anxiety</i>	22.979 (0.123), <0.001	2.430 (0.021), >0.100	0.633 (0.004), <0.001	0.737 (0.009), <0.001
<i>Age</i>	17.698 (0.031), <0.001	1.399 (0.005), <0.001	0.007 (0.001), <0.001	786 (0.002), <0.001
<i>Attendance at Emergency Department</i>	9.282 (0.018), <0.001	—	—	—

*Deprivation quintile based on Welsh Index of Multiple Deprivation 2011. WIMD1 = most deprived, WIMD5 = least deprived ** p -value < 0.05 = significant.




Figure 3. Comparison of healthcare costs in all sectors between 2005 and 2015 in Wales. Stratified by case subjects (in receipt of opioid analgesics) and control subjects (not receiving opioid analgesics). Average costs per subject given in GBP (£) using unit costs from 2015.^{44,45,67}

Table 4. Average costings for healthcare utilisation comparing all subjects within the study, cases and controls.

	Mean average costs (£) (standard error of the mean)				
	All subjects (n = 3 286 215)	Cases (n = 657 243)	Controls (n = 2 628 972)	Difference case -controls (95% CI)	p-value* (effect size d)
Primary care	2003.23 (1.85)	5530.77 (6.22)	1121.34 (1.21)	4409.43 (4397.01–4421.84)	<0.001 (0.96)
Emergency department	112.81 (0.16)	249.62 (0.55)	78.61 (0.14)	171.01 (169.89–172.12)	<0.001 (0.42)
Secondary Care					
Outpatient attendance	744.69 (0.79)	1530.43 (2.34)	548.26 (0.68)	982.18 (976.84–987.52)	<0.001 (0.50)
Day-case attendance	779.64 (2.01)	1605.80 (5.46)	573.10 (2.09)	1032.70 (1021.25–1044.51)	<0.001 (0.24)
Total inpatient	7456.11 (13.94)	7536.73 (27.97)	7435.96 (15.96)	100.77 (32.20–37.66)	<0.001 (0.004)
Total secondary care	8235.76 (14.27)	9142.53 (29.25)	8009.06 (16.27)	1133.47 (1067.88–1199.07)	<0.001 (0.05)
Total healthcare costs	11096.49 (15.03)	16453.35 (33.08)	9757.27 (16.77)	6696.08 (6623.39–6768.77)	<0.001 (0.25)
Prescribing persistence (cases only)					
<6 months		8835.89 (46.94)			
>6 months		19603.49 (41.68)		10767.60 (10644.57–10890.62)	<0.001 (0.47)
Deprivation quintile**					
WIMD1	11728.52 (31.75)	17509.49 (72.18)	10283.28 (35.11)	7226.21 (7068.89–7383.53)	<0.001 (0.26)
WIMD2	11445.45 (35.64)	16953.81 (74.62)	10068.36 (40.24)	6885.45 (6719.28–7051.62)	<0.001 (0.25)
WIMD3	11678.32 (32.28)	16489.79 (71.41)	10475.45 (36.00)	6014.34 (5857.60–6171.08)	<0.001 (0.23)
WIMD4	10050.70 (32.21)	15530.13 (74.56)	8680.84 (35.40)	6849.29 (6687.53–7011.05)	<0.001 (0.28)
WIMD5	10177.81 (35.44)	15322.23 (75.78)	8891.71 (39.82)	6430.52 (6262.73–6598.31)	<0.001 (0.25)
Sensitivity analysis increase to control subjects' costs					
50%		16453.35 (33.08)	14635.91 (25.15)	1817.45 (1736.00–1898.89)	<0.001 (0.06)
75%		16453.35 (33.08)	17075.22 (29.34)	–621.87 (–708.54 to –535.21)	<0.001 (–0.02)

*p-value calculated from t-test (case-control), <0.05 = significant Bonferroni–Holm tests confirmed it was correct to reject the null hypothesis **Deprivation quintile based on Welsh Index of Multiple Deprivation 2011. WIMD1 = most deprived, WIMD5 = least deprived.

provide a more accurate assessment of PP. Prescribing data suggests intention to treat but does not identify the dose or quantity of medicine prescribed nor confirms consumption. Quality of life measurements are not routinely recorded in practice, so further research is needed to develop cost-utility analyses.

Future research to examine the relationship between the duration of opioid use and the timing of changes in healthcare utilisation could provide insight into safe durations of opioid use, which would positively impact clinical guidance. In addition, it would be useful to identify if people who have stopped using opioid analgesics see a corresponding reduction in their use of healthcare services.

Conclusions

Our results show a likely association between the receipt of opioid analgesic prescriptions and increased

healthcare utilisation and costs for people living with commonly occurring conditions such as back pain, osteoarthritis and fibromyalgia. Some individuals prescribed opioids may be more unwell than those who do not receive them, so further investigation of whether the use of opioid analgesics is potentiating underlying health conditions would be beneficial. Long-term and high-dose opioid analgesic use has been associated with higher levels of pain reporting and worse outcomes^{60,64,62} including self-reported poor general health,⁶⁰ depression^{35,65} and polypharmacy.⁶⁶ This is especially pertinent in Wales, a country where an estimated 23% of the population live in poverty,⁶⁷ 61% are overweight or obese⁶⁸ and an average 26 prescriptions for any medicines are issued annually, per head of population compared to 19.9 prescriptions per head in England.⁶⁹

Given concerns about high levels of opioid use in the United Kingdom and internationally,

consideration of the wider impact on people's health that opioids may have is possibly as important as the well-publicised concerns about misuse and dependence. This could be especially pertinent in the wake of the COVID-19 pandemic, when people living with long-term, painful conditions might expect delays to treatment or intervention. Practitioners in all sectors of healthcare provision may find themselves under greater pressure to provide analgesic medicines, whilst individuals wait to be seen elsewhere. Additionally, some reported symptoms of long-COVID⁶⁸ are very similar to widespread pain conditions like fibromyalgia, which is known not to respond well to opioids in most cases^{69,70} but where opioids are often still given, perhaps due to the paucity of timely alternatives.¹⁰ The decision to initiate opioid analgesics must be carefully weighed with potential risks of increasing healthcare need, rather than reducing it, unless regular review and limiting duration of use can be supported.

Acknowledgements

This study makes use of anonymised data generated by the Secure Anonymized Information Linkage (SAIL) system, which is part of the national e-health records research infrastructure for Wales. We would like to acknowledge all the data providers who make anonymised data available for research.

Declaration of conflicting interest

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Pharmacy Research UK grant number PRUK-2016-PA1-A. ED's PhD is partly supported by funding from Research Capacity Building Collaboration (RCBC Wales).

Ethical approval

Ethical approval (*include full name of committee approving the research and if available mention reference number of that approval*): Ethical approval was not sought for the present study because the SAIL databank provides anonymised person level data with means of identification removed prior to submission to the databank. The Information Governance Review Panel (IGRP) of SAIL quality assures all applications for access and considers ethical implications prior to study approval. This study was completed in accordance with the Helsinki Declaration as revised in 2013.

Guarantor

E.D

Contributorship

ED. conceived of and designed the study, collated the read codes used for data extraction, coded the extracted data, undertook the data analysis, drafted and revised the article. MJ, CP and BS oversaw the study design and data analysis and critically revised the article. All authors read and approved the final article.

ORCID iD

Emma Davies  <https://orcid.org/0000-0003-1171-3201>

Supplementary material

Supplementary Material is available for the article.

References

1. Zin CS, Chen LC and Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. *Eur J Pain* [Internet] 2014; 18(9): 1343–1351. Available at: <https://nottingham-repository.worktribe.com/output/1100471>.
2. Jani M, Birlie Yimer B, Sheppard T, et al. Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study. *PLoS Med* 2020 Oct 8; 17(10): e1003270.
3. Davies E, Phillips C, Rance J, et al. Examining patterns in opioid prescribing for non-cancer related pain in wales: preliminary data from a retrospective cross-sectional study using large datasets. *Br J Pain* 2018; 13(3): 145–158.
4. Ruscitto A, Smith BH and Guthrie B. Changes in opioid and other analgesic use 1995–2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. *Eur J Pain* 2015; 19(1): 59–66.
5. Curtis HJ, Croker R, Walker AJ, et al. Opioid prescribing trends and geographical variation in England, 1998–2018: a retrospective database study. *Lancet Psychiatry* [Internet] 2019; 6(2): 140–150. Available at: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=30580987&retmode=ref&cmd=prlinks>.
6. Foy R, Leaman B, McCrorie C, et al. Prescribed opioids in primary care: cross-sectional and longitudinal analyses of influence of patient and practice characteristics. *BMJ Open* [Internet] 2018; 6(5): e010276. Available at: <https://bmjopen.bmj.com/content/bmjopen/6/5/e010276.full.pdf>.
7. Mordecai L, Reynolds C, Donaldson LJ, et al. Patterns of regional variation of opioid prescribing in primary care in England: a retrospective observational study. *Br J Gen Pract* 2018; 68(668): e225–e233.

8. Smith BH, Fletcher EH and Colvin LA. Opioid prescribing is rising in many countries. *BMJ* [Internet] 2019; 367: 15823. Available at: <https://www.bmj.com/content/367/bmj.15823>.
9. Davies E, Sewell B, Jones M, et al. Examining opioid prescribing trends for non-cancer pain using an estimated oral morphine equivalence measure: a retrospective cohort study between 2005 and 2015. *BJGP Open* [Internet] 2020; 17(8): bjgpopen20X101122–13. Available at: <http://bjgpopen.org/lookup/doi/10.3399/bjgpopen20X101122>.
10. Jackson T, Thomas S, Stabile V, et al. Prevalence of chronic pain in low-income and middle income countries: a systematic review and meta-analysis. *Lancet* 2015; 385: S10.
11. Fayaz A, Croft P, Langford RM, et al. Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. *Bmj Open* 2016; 6(6): e010364.
12. Mansfield KE, Sim J, Jordan JL, et al. A systematic review and meta-analysis of the prevalence of chronic widespread pain in the general population. *Pain* 2016; 157(1): 55–64.
13. Ballantyne JC, Kalso E and Stannard C. WHO analgesic ladder: a good concept gone astray. *BMJ* 2016; 352: i20–2.
14. Weisberg D and Stannard C. Lost in translation? Learning from the opioid epidemic in the USA. *Anaesthesia* 2013; 68(12): 1215–1219.
15. McCrorie C, Closs SJ, House A, et al. Understanding long-term opioid prescribing for non-cancer pain in primary care: a qualitative study. *Bmc Fam Pract* [Internet] 2015; 16(1): 121–129. DOI: 10.1186/s12875-015-0335-5.
16. Finestone HM, Juurlink DN, Power B, et al. Opioid prescribing is a surrogate for inadequate pain management resources. *Arch Intern Med* [Internet] 2016; 62(6): 465–468. Available at: <http://www.cfp.ca/content/62/6/465.full>.
17. Phillips CJ. Economic burden of chronic pain. *Expert Rev Pharm Out* [Internet] 2006; 6(5): 591–601. DOI: 10.1586/14737167.6.5.591.
18. Phillips CJ and Harper C. The economics associated with persistent pain. *Curr Opin Support Pa* [Internet] 2011; 5(2): 127–130. Available at: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?dbfrom=pubmed&id=21430542&retmode=ref&cmd=prlinks>.
19. Maniadakis N and Gray A. The economic burden of back pain in the UK. *Pain* [Internet] 2000; 84(1): 95–103. Available at: <http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104718901&site=ehost-live&scope=site&authtype=shib&custid=s8000044>
20. Ballantyne JC and LaForge KS. Opioids dependence and addiction during opioid treatment of chronic pain. *Pain* 2007; 129: 235–255.
21. Minozzi S, Amato L and Davoli M. Development of dependence following treatment with opioid analgesics for pain relief: a systematic review. *Addiction* [Internet] 2013; 108(4): 688–698. Available at: <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1360-0443.2012.04005.x>.
22. Shapiro H. *Opioid painkiller dependency (OPD): an overview. A report written for the all-party parliamentary group on prescribed medicine dependency* [Internet]. London: Drug Wise, 2015, pp. 1–18. Available at: http://www.drugwise.org.uk/wp-content/uploads/opioid_painkiller_dependency_final_report_sept_201.pdf.
23. Campbell G, Nielsen S, Larance B, et al. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. *Pain Med* [Internet] 2015; 16(9): 1745–1758. DOI: 10.1111/pme.12773.
24. Ellis RJ, Wang Z, Genes N, et al. Predicting opioid dependence from electronic health records with machine learning. *Biodata Min* 2019; 12(1): 3–19.
25. Strassels S. Economic burden of prescription opioid misuse and abuse. *J Manag Care Pharm* [Internet] 2009; 15(7): 556–562. Available at: <https://www.jmcp.org/doi/pdf/https://www.jmcp.org/doi/pdf/10.18553/jmcp.2009.15.7.556>.
26. Shei A, Hirst M, Kirson NY, et al. Estimating the health care burden of prescription opioid abuse in five European countries. *Clinicoecon Outcomes Res* [Internet] 2015; 7: 477, Available at: <https://pubmed.ncbi.nlm.nih.gov/26396536>.
27. Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared with placebo or other treatments for chronic low back pain. *Spine* 2014; 39(7): 556–563.
28. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among veterans health administration patients. *Pain Med* [Internet] 2014; 15(11): 1911–1929. Available at: <https://academic.oup.com/painmedicine/article/15/11/1911/1835923>.
29. Baldini A, Von Korff M and Lin EH. A review of potential adverse effects of long-term opioid therapy: a practitioner's guide. *Prim Care Companion Cns Disord* [Internet] 2012; 14(3), PCC 11m01326. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466038/>.
30. Kane-Gill SL, Rubin EC, Smithburger PL, et al. The cost of opioid-related adverse drug events. *J Pain Palliat Care Pharmacother* 2014; 28(3): 282–293.
31. Ivanova JI, Birnbaum HG, Yushkina Y, et al. The prevalence and economic impact of prescription opioid-related side effects among patients with chronic non-cancer pain. *J opioid management* [Internet] 2013; 9(4): 239–254. Available at: <http://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=107928790&>

- site=ehost-live&scope=site&authtype=shib&custid=s8000044.
32. Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of cochrane reviews. *Cochrane Db Syst Rev* [Internet] 2017; 10(10): CD012509. Available at: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29084357&retmode=ref&cmd=prlinks>.
 33. Seyfried O and Hester J. Opioids and endocrine dysfunction. *Br J Pain* 2012; 6(1): 17–24.
 34. Fischer B, Murphy Y, Kurdyak P, et al. Depression - a major but neglected consequence contributing to the health toll from prescription opioids? *Psychiat Res* 2016; 243: 331–334.
 35. Mazereeuw G, Sullivan MD and Juurlink DN. Depression in chronic pain: might opioids be responsible? *Pain*. *Pain* 2018; 159(11): 2142–2145.
 36. Rose AR, Catcheside PG, McEvoy RD, et al. Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long term opioid therapy. *J Clin Sleep Med* 2014; 10(8): 847–852.
 37. Gupta K, Nagappa M, Prasad A, et al. Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses. *BMJ Open* 2018; 8(12): e024086.
 38. Morasco BJ, O’Hearn D, Turk DC, et al. Associations between prescription opioid use and sleep impairment among veterans with chronic pain. *Pain Med* 2014; 15(11): 1902–1910.
 39. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. *J Gen Intern Med* [Internet] 2010; 25(4): 310–315, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842546/pdf/11606_2009_Article_1218.pdf.
 40. Miller M, Stürmer T, Azrael D, et al. Opioid analgesics and the risk of fractures in older adults with arthritis. *J Am Geriatr Soc* 2011; 59(3): 430–438.
 41. Yoshikawa A, Ramirez G, Smith ML, et al. Opioid use and the risk of falls, fall injuries and fractures among older adults: a systematic review and meta-analysis. *J Gerontol Ser* 2020; 75(10): 1989–1995.
 42. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. *BMC Med Inform Decis Mak* [Internet] 2009; 9(1): 3. Available at: <http://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/1472-6947-9-3>.
 43. Ford DV, Jones KH, Verplancke J-P, et al. The SAIL databank: building a national architecture for e-health research and evaluation. *BMC Health Serv Res* 2009; 9: 157.
 44. (SAIL)Databank SAIL. The SAIL databank. n.d.; Available at: <https://saildatabank.com/>.
 45. StatsWales. Welsh index of multiple deprivation 2011 by rank and local super output area [Internet]. n.d. [cited 2021 May 12]. Available at: <https://statswales.gov.wales/Catalogue/Community-Safety-and-Social-Inclusion/Welsh-Index-of-Multiple-Deprivation/Archive/WIMD-2011/wimd2011>.
 46. Joint Formulary Committee. *Prescribing in palliative care. BNF: British National Formulary - NICE* [Internet]. London: BMJ Group and Pharmaceutical Press; 2021 [cited 2021 Aug 10]. Available from: <https://bnf.nice.org.uk/guidance/prescribing-in-palliative-care.html>
 47. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. *Arch Intern Med* 2010; 170(16): 1425–1432.
 48. Field. *A. Discovering statistics using IBM SPSS statistics*. 4th ed. London: SAGE Publications, 2013.
 49. Corporation of IBM. *IBM SPSS statistics for windows, Version 26.0*. Armonk, NY: IBM Corporation, n.d.
 50. Eichstaedt KE, Kovatch K and Maroof DA. A less conservative method to adjust for familywise error rate in neuropsychological research: the Holm’s sequential Bonferroni procedure. *NeuroRehabilitation* 2013; 32(3): 693–696.
 51. Curtis L and Burns A. *Unit Costs of Health and Social Care 2015* [Internet]. Canterbury: Personal Social Services Research Unit, University of Kent; 2015. Available from: <https://www.pssru.ac.uk/pub/uc/uc2015/full.pdf>
 52. Department of Health and Social Care. *NHS reference costs 2014 to 2015* [Internet]. 2015 [cited 2020 May 20]. Available at: <https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015>.
 53. Hippisley-Cox J and Vinogradova Y. *Trends in consultation rates in general practice 1995/1996 to 2008/2009: analysis of the QResearch® database* [Internet] [Internet]. 2009; pp. 1–23. Available at: <https://files.digital.nhs.uk/publicationimport/pub01xxx/pub01077/trends-cons-rate-gene-prac-95-09-95-08-rep.pdf>.
 54. Green K, Cooke O’Dowd N., Watt H, et al. Prescribing trends of gabapentin, pregabalin, and oxycodone: a secondary analysis of primary care prescribing patterns in England. *BJGP Open* 2019; 3(3): bjgpopen19X101662.
 55. Fischer B and Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. *Pain Physician* [Internet] 2012; 15(3 Suppl): ES191–ES203. Available at: <http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=22786457&retmode=ref&cmd=prlinks>.
 56. Adverse effects of opioids for non-cancer pain. *Drug Ther Bull* [Internet]. 2018; 56(2): 15–16. Available at: <https://dtb.bmj.com/content/56/2/15.2.full.pdf>
 57. Stannard CF. Pain and pain prescribing: what is in a number? *Br J Anaesth* [Internet] 2018; 120(6): 1147–1149, Available at: <https://linkinghub.elsevier.com/retrieve/pii/S0007091218301806>.
 58. Bruggenjurgen B, Burkwitz J and Willich SN. Utilisation of medical resources of patients with pain undergoing an outpatient opioid therapy. *Gesundheitswesen (Bundesverband*

- der Ärzte des Öffentlichen Gesundheitsdienstes (Germany))* 2007; 69(6): 353–358.
59. Kern DM, Zhou S, Chavoshi S, et al. Treatment patterns, healthcare utilization, and costs of chronic opioid treatment for non-cancer pain in the United States. *Am J Manag Care* [Internet] 2015; 21(3): e222–e234. Available at: <https://www.ajmc.com/view/treatment-patterns-healthcare-utilization-and-costs-of-chronic-opioid-treatment-for-non-cancer-pain-in-the-united-states>.
 60. Macfarlane GJ, Beasley M, Jones GT, et al. The epidemiology of regular opioid use and its association with mortality: prospective cohort study of 466 486 UK biobank participants. *EClinicalMedicine* 2020; 21: 1–8.
 61. Thornton D, Dwibedi N, Scott V, et al. Increased healthcare utilization and expenditures associated with chronic opioid therapy. *AJMC* 2018; 6(4): 11–18.
 62. Cicero TJ, Wong G, Tian Y, et al. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. *Pain* 2009; 144(1): 20–27.
 63. Sail Analyst. *Personal communication. Data extraction meeting.* 2017.
 64. Todd A, Akhter N, Cairns J-M, et al. The pain divide: a cross-sectional analysis of chronic pain prevalence, pain intensity and opioid utilisation in England. *BMJ Open* 2018; 8(7): e023391.
 65. Rosoff DB, Smith GD and Lohoff FW. Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders. *Jama Psychiatry* 2021; 78(2): 151–160.
 66. Richards GC, Mahtani KR, Muthee TB, et al. Factors associated with the prescribing of high-dose opioids in primary care: a systematic review and meta-analysis. *BMC Med* 2020; 18(1): 68.
 67. Barnard H. Poverty in wales 2018. 2018; pp. 1–34. Available at: <https://www.jrf.org.uk>.
 68. Welsh Government. *National survey for wales 2019-20: adult lifestyle* [Internet]. 2020, pp. 1–19. Cardiff: Welsh Government. Available at: <https://gov.wales/sites/default/files/statistics-and-research/2020-07/adult-lifestyle-national-survey-wales-april-2019-march-2020-390.pdf>.
 69. Welsh government. Prescriptions in wales, 2019-20 [Internet]. 2020. Available at: <https://gov.wales/sites/default/files/statistics-and-research/2020-09/prescriptions-wales-april-2019-march-2020-610.pdf>.
 70. National Health Service. Long-term effects of coronavirus (long COVID) [Internet]. 2021 [cited 2021 Jul 4]. Available at: <https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid/>.
 71. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. *Ann Rheum Dis* 2017; 76(2): 318–328.
 72. Kia S and Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. *Biomed* 2017; 5(2): 20.
 73. Morasco BJ, Yarborough BJ, Smith NX, et al. Higher prescription opioid dose is associated with worse patient-reported pain outcomes and more health care utilization. *J Pain* 2017; 18(4): 437–445.